Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and d...

Full description

Bibliographic Details
Main Authors: Joanna Mangana, Christian Posch, Christoph Hoeller, Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Sofiya Latifyan, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Julian Kofler, Christine Hafner
Format: Article
Language:English
Published: BMJ Publishing Group 2021-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/2/e001701.full

Internet

https://jitc.bmj.com/content/9/2/e001701.full

Similar Items